We are live on
!
Find out more
DY
Dowling & Yahnke Portfolio holdings
AUM
$2.15B
Turnover
6.98%
1-Year Est. Return
10.82%
This Fund
S&P 500
This Quarter
Est. Return
+6.63%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$1.74B
AUM Growth
+$276M
(+19%)
Cap. Flow
+$178M
Cap. Flow
% of AUM
10.22%
Top 10 Holdings %
Top 10 Hldgs %
26.57%
Holding
376
New
39
Increased
143
Reduced
134
Closed
9
Avg Time Held
4.5
years
Top 10 Avg Time Held
2.7
years
Top 20 Avg Time Held
2.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dimensional US Equity ETF
DFUS
|
+$53.3M |
| 2 |
U.S. Targeted Value Portfolio ETF Class Shares
DFAT
|
+$48.6M |
| 3 |
U.S. Core Equity 2 Portfolio ETF Class Shares
DFAC
|
+$28.7M |
| 4 |
U.S. Small Cap Portfolio ETF Class Shares
DFAS
|
+$28.3M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$5.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$1.93M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$1.82M |
| 3 |
Vanguard Morningstar Small-Cap ETF
VB
|
+$1.7M |
| 4 |
The Marzetti Company
MZTI
|
+$1.18M |
| 5 |
iShares Micro-Cap ETF
IWC
|
+$1.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 31.47% |
| 2 | Technology | 15.8% |
| 3 | Financials | 10.71% |
| 4 | Healthcare | 10.19% |
| 5 | Consumer Staples | 7.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TWTR
351
DELISTED
Twitter, Inc.
TWTR
| $210K | 0.01% |
+3,055
| New | +$187K |
2021 Q2
0 quarters
|
|
352
iShares Core S&P US Growth ETF
IUSG
$33.6B
| $209K | 0.01% |
2,073
-890
| -30% | -$85.8K |
2021 Q1
1 quarter
|
|
353
Ares Capital
ARCC
$13.5B
| $208K | 0.01% |
10,620
| – | – |
2020 Q4
2 quarters
|
|
354
Schwab US TIPS ETF
SCHP
$16.4B
| $204K | 0.01% |
+6,512
| New | +$202K |
2021 Q2
0 quarters
|
|
355
Worthington Enterprises
WOR
$3.17B
| $204K | 0.01% |
5,421
| – | – |
2021 Q1
1 quarter
|
|
356
Allstate
ALL
$61.5B
| $202K | 0.01% |
+1,548
| New | +$200K |
2021 Q2
0 quarters
|
|
357
Cintas
CTAS
$84.6B
| $202K | 0.01% |
2,120
-352
| -14% | -$31.2K |
2020 Q3
3 quarters
|
|
358
Guggenheim Strategic Opportunities Fund
GOF
$1.91B
| $201K | 0.01% |
+9,267
| New | +$195K |
2021 Q2
0 quarters
|
|
359
iShares US Financials ETF
IYF
$3.86B
| $200K | 0.01% |
+2,470
| New | +$199K |
2021 Q2
0 quarters
|
|
|
GPX
360
DELISTED
GP Strategies Corp.
GPX
| $194K | 0.01% |
12,326
+641
| +5% | +$10.4K |
2020 Q4
2 quarters
|
|
361
Grifois
GRFS
$5.25B
| $190K | 0.01% |
10,969
+14
| +0.1% | +$251 |
2013 Q2
32 quarters
|
|
362
iShares US Oil Equipment & Services ETF
IEZ
$339M
| $153K | 0.01% |
10,000
| – | – |
2020 Q4
2 quarters
|
|
363
Strata Critical Medical Inc
SRTA
$405M
| $105K | 0.01% |
+10,000
| New | +$98.7K |
2021 Q2
0 quarters
|
|
|
ADMS
364
DELISTED
Adamas Pharmaceuticals
ADMS
| $84K | ﹤0.01% |
16,000
+3,000
| +23% | +$15.5K |
2019 Q3
7 quarters
|
|
365
Fortress Biotech
FBIO
$62.7M
| $71K | ﹤0.01% |
1,333
| – | – |
2019 Q1
9 quarters
|
|
366
Geron
GERN
$765M
| $55K | ﹤0.01% |
39,047
| – | – |
2020 Q4
2 quarters
|
|
367
DELISTED
Regulus Therapeutics
RGLS
| $10K | ﹤0.01% |
1,200
| – | – |
2020 Q2
4 quarters
|
|
368
Alibaba
BABA
$273B
| – | – |
-1,390
| Closed | -$315K | – |
|
369
BioCryst Pharmaceuticals
BCRX
$2.01B
| – | – |
-11,000
| Closed | -$112K | – |
|
370
CrowdStrike
CRWD
$231B
| – | – |
-7,028
| Closed | -$321K | – |
|
371
Corteva
CTVA
$8.61B
| – | – |
-4,300
| Closed | -$200K | – |
|
372
Kyntra Bio
KYNB
$21.3M
| – | – |
-258
| Closed | -$224K | – |
|
373
New Mountain Finance
NMFC
$641M
| – | – |
-34,325
| Closed | -$426K | – |
|
374
Sixth Street Specialty
TSLX
$1.64B
| – | – |
-19,374
| Closed | -$407K | – |
|
375
TSMC
TSM
$2.15T
| – | – |
-2,112
| Closed | -$250K | – |
|
Similar funds
AC
APA
IC
SCA
ACM
W
Dowling & Yahnke's Q2 2021 Portfolio in Review
As of Q2 2021, Dowling & Yahnke held 376 positions worth $1.74B, up 19% from $1.46B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Dowling & Yahnke deployed $178M of net new capital in Q2 2021, opening 39 new positions and adding to 143 existing holdings. Its largest new stake was Dimensional US Equity ETF: 1,143,816 shares worth $53.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 31% of assets, up from 25% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Bank of America, an estimated $1.93M trimmed.
- Dowling & Yahnke's largest Q2 2021 buy was Dimensional US Equity ETF: 1,143,816 shares worth $53.9M.
- Dowling & Yahnke added most to Vanguard S&P 500 ETF in Q2 2021, an estimated $5.26M increase.
- Dowling & Yahnke's biggest Q2 2021 reduction was Bank of America, cutting an estimated $1.93M.
- Dowling & Yahnke fully exited GW Pharmaceuticals Plc American Depositary Shares in Q2 2021, selling an estimated $1.82M.
- Dowling & Yahnke's ten largest holdings make up 27% of its $1.74B portfolio in Q2 2021.
- Dowling & Yahnke opened 39 new positions and closed 9 in Q2 2021.
- Dowling & Yahnke's portfolio value rose 19% quarter-over-quarter to $1.74B.
Based on Dowling & Yahnke's 13F filing for Q2 2021, filed 21 Jul 2021.